Multi-Center Trial of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints

Stereotactic body radiotherapy (SBRT) offers a cost-effective method to escalate dose in early-stage prostate cancer. Although results from single-institutions series are promising, mature data from large multi-center trials are lacking. We treated, across 21 centers, 309 patients with low- and intermediate-risk prostate cancer. With median follow-up exceeding 5 years, rates of grade 3+ toxicities were low (1.3%), and biochemical disease-free survival compared favorably to historical controls. SBRT is a suitable option for early-stage prostate cancer.

https://ift.tt/2J54Hb4